Kakyung Kim

Archives
Log in
Subscribe
October 30, 2026

๐Ÿ“ˆ econ-radar 2026-10-30 ยท mRNA ๊ฐœ์ธ๋งž์ถค ์•”๋ฐฑ์‹ (Personalized mRNA Cancer Vaccine)

๐Ÿ“ˆ econ-radar 2026-10-30 ยท mRNA ๊ฐœ์ธ๋งž์ถค ์•”๋ฐฑ์‹ (Personalized mRNA Cancer Vaccine)

๐Ÿ“ˆ econ-radar ๋ฐ์ผ๋ฆฌ

2026-10-30

์ œ์•ฝยท๋ฐ”์ด์˜คยทAI์— ๋ฌด๊ฒŒ๋ฅผ ๋‘” ๊ฒฝ์ œ ๋ฐ์ผ๋ฆฌ โ€” ์‚ฐ์—…๊ตฌ์กฐยทํˆฌ์žยท์‹œ์žฅ 3๋ Œ์ฆˆ

At a Glance

๐Ÿ’ฐ ๋ฏธ๊ตญยทํ•œ๊ตญ GDP๊ฐ€ ๊ฐ™์€ ๋‚  ์ปจ์„ผ์„œ์Šค๋ฅผ ์›ƒ๋Œ๋ฉฐ ๊ฒฝ๊ธฐ ๊ฐ•์„ธ๋ฅผ ํ™•์ธํ–ˆ๋‹ค. ๋Œ€์‹  FOMC 12์›” ์ธ์ƒ ํ™•๋ฅ (OIS ~80%)๋„ ํ•จ๊ป˜ ๊ตณ์–ด์กŒ๋‹ค.

๐Ÿงฌ ESMO 2026์ด ํ•ญ์•” ์‹ ์•ฝ์˜ ์„ธ๋Œ€ ์ „ํ™˜์„ ๊ธฐ๋กํ•œ ๋‚ ๋กœ ๋งˆ๋ฌด๋ฆฌ๋๋‹ค. mRNA ๊ฐœ์ธ๋งž์ถค ์•”๋ฐฑ์‹ ๊ณผ KRAS 3์„ธ๋Œ€ ์–ต์ œ์ œ๊ฐ€ Phase 3 ๋ฐ์ดํ„ฐ๋ฅผ ๊ฐ™์€ ๋‚  NEJM์— ์‹ค์—ˆ๋‹ค.

๐Ÿค– ๋น…ํ…Œํฌ AI ํด๋ผ์šฐ๋“œ ์–ด๋‹์Šค ์‹œ์ฆŒ์ด ์™„๊ฒฐ๋๋‹ค. ์„ธ ํšŒ์‚ฌ ๋ชจ๋‘ ์„ฑ์žฅํ–ˆ์ง€๋งŒ ์ด์ต์œผ๋กœ ์ „ํ™˜ํ•œ ์†๋„๋Š” ๋‹ฌ๋ž๊ณ , ์‹œ์žฅ์€ ๊ทธ ์ฐจ์ด๋ฅผ ์ฃผ๊ฐ€์— ๋ฐ˜์˜ํ–ˆ๋‹ค.

Today's Top 5

Bio

1. intismeran autogene INTerpath-001 Phase 3 โ€” ํ‘์ƒ‰์ข… mRNA ๊ฐœ์ธ๋งž์ถค ์•”๋ฐฑ์‹ , ํ•ญ์•” Phase 3 ์ฒซ ์„ฑ๊ณต

Merck(๋จธํฌ)์™€ Moderna(๋ชจ๋”๋‚˜)์˜ ๊ฐœ์ธ๋งž์ถค mRNA ์•”๋ฐฑ์‹  intismeran autogene(์ธํ‹ฐ์Šค๋ฉ”๋ž€ ์˜คํ† ์  )์„ pembrolizumab(ํŽจ๋ธŒ๋กค๋ฆฌ์ฃผ๋ง™ยทํ‚คํŠธ๋ฃจ๋‹ค)๊ณผ ๋ณ‘์šฉํ•œ Phase 3 INTerpath-001 ๊ฒฐ๊ณผ๊ฐ€ ESMO 2026 ์ตœ์šฐ์„  ๋ฐœํ‘œ(LBA1)๋กœ ๊ณต๊ฐœ๋๋‹ค. ์ˆ˜์ˆ  ์™„์ „ ์ ˆ์ œ ํ›„ ๋ณ‘๊ธฐ IIB~IV ํ‘์ƒ‰์ข…(melanoma) ํ™˜์ž 1,137๋ช…์„ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์‹œํ—˜์—์„œ ์žฌ๋ฐœยท์‚ฌ๋ง ์œ„ํ—˜์ด 42% ์ค„์—ˆ๊ณ (์žฌ๋ฐœ์—†๋Š”์ƒ์กด์œจ(RFS, Recurrence-Free Survival) HR 0.58, p<0.001), ์›๊ฒฉ์ „์ดยท์‚ฌ๋ง ์œ„ํ—˜๋„ 38% ๋‚ฎ์•„์กŒ๋‹ค(์›๊ฒฉ๋ฌด์ „์ด์ƒ์กด์œจ(DMFS, Distant Metastasis-Free Survival) HR 0.62(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”), p=0.002). NEJM์— ๋™์‹œ ๊ฒŒ์žฌ๋์œผ๋ฉฐ ๋‘ ํšŒ์‚ฌ๋Š” ๊ทœ์ œ ๋‹น๊ตญ๊ณผ ๊ต์„ญ์„ ์ง„ํ–‰ ์ค‘์ด๋ผ๊ณ  ๋ฐํ˜”๋‹ค.

โ†— OncLive โ€” INTerpath-001

Bio

2. divarasib KrasCendo-1 Phase 3 โ€” KRAS G12C 3์„ธ๋Œ€, sotorasibยทadagrasib ๋™์‹œ ์ถ”์›”

Roche(๋กœ์Šˆ)/Genentech์˜ ๋””๋ฐ”๋ผ์‹ญ(divarasib)์ด ์ด์ „ ์น˜๋ฃŒ๋ฐ›์€ KRAS G12C ๋Œ์—ฐ๋ณ€์ด ๋น„์†Œ์„ธํฌํ์•”(NSCLC, Non-Small Cell Lung Cancer) 2์ฐจ ์น˜๋ฃŒ์—์„œ sotorasib(์†Œํ† ๋ผ์‹ญยทAmgen)๊ณผ adagrasib(์•„๋‹ค๊ทธ๋ผ์‹ญยทBlueprint/MSD)๋ฅผ ์ง์ ‘ ๋น„๊ต(head-to-head) Phase 3 KrasCendo-1์—์„œ PFSยทOS ๋ชจ๋‘ ์ด๊ธด ์„ธ๋ถ€ ์ˆ˜์น˜๋ฅผ ESMO 2026์—์„œ ๊ณต๊ฐœํ–ˆ๋‹ค. ๋ฌด์ง„ํ–‰์ƒ์กด๊ธฐ๊ฐ„(PFS) ์ค‘์•™๊ฐ’ 9.8๊ฐœ์›” ๋Œ€ 5.7๊ฐœ์›”(HR 0.58, p<0.0001), ์ „์ฒด์ƒ์กด๊ธฐ๊ฐ„(OS) ์ค‘์•™๊ฐ’ 17.7๊ฐœ์›” ๋Œ€ 12.0๊ฐœ์›”(HR 0.56, p<0.001)์ด๋‹ค. NEJM์— ๋™์‹œ ๊ฒŒ์žฌ๋๋‹ค(DOI 10.1056/NEJMoa2605703). ์–ด์ œ raw์—์„œ ์ˆ˜์น˜ ๋ฏธํ™•์ธ์ด์—ˆ๋˜ ํ•ญ๋ชฉ์œผ๋กœ, ์˜ค๋Š˜ ์„ธ๋ถ€ HR์ด ํ™•์ •๋๋‹ค.

โ†— OncLive โ€” PFSยทOS HR

AI

3. Amazon Q3 + AI ํด๋ผ์šฐ๋“œ ์–ด๋‹์Šค ์ด๊ฒฐ์‚ฐ โ€” AWS $46B(+39.3%), 2027 capex "materially higher"

Amazon(์•„๋งˆ์กด)์ด Q3 2026 ์ „์‚ฌ ๋งค์ถœ 2,019์–ต๋‹ฌ๋Ÿฌ(์•ฝ 279์กฐ6,000์–ต์›, +12% YoY), ์ „์‚ฌ ์˜์—…์ด์ต 281์–ต๋‹ฌ๋Ÿฌ(์•ฝ 38์กฐ9,000์–ต์›, +61% YoY)๋ฅผ ๋ฐœํ‘œํ–ˆ๋‹ค. ์˜์—…์ด์ต๋ฅ (OPM) 13.9%(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”)๋Š” ์—ญ๋Œ€ ์ตœ๊ณ ์น˜๋‹ค. AWS๋Š” ๋ถ„๊ธฐ ๋งค์ถœ 460์–ต๋‹ฌ๋Ÿฌ(์•ฝ 63์กฐ7,000์–ต์›, +39.3% YoY)(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”)๋กœ Q2(+36.7%)์—์„œ ๊ฐ€์†ํ–ˆ๊ณ , AWS ์˜์—…์ด์ต์€ 178์–ต๋‹ฌ๋Ÿฌ(์•ฝ 24์กฐ7,000์–ต์›, OPM 38.7%)์˜€๋‹ค. Q4 ๊ฐ€์ด๋˜์Šค๋Š” ๋งค์ถœ 2,400~2,470์–ต๋‹ฌ๋Ÿฌ(์•ฝ 332์กฐ4,000์–ต~342์กฐ1,000์–ต์›)๋‹ค. Andy Jassy CEO๋Š” "2027ยท2028๋…„์—๋„ AWS ์„ฑ์žฅ๋ฅ ์ด 40%๋ฅผ ๋„˜์„ ๊ฒƒ"์ด๋ผ๊ณ  ๋ฐํ˜”๋‹ค. ๋ฐ˜๋ฉด 2027๋…„ ์„ค๋น„ํˆฌ์ž(capex)๊ฐ€ 2026๋…„(์•ฝ 2,200์–ต๋‹ฌ๋Ÿฌยท์•ฝ 304์กฐ7,000์–ต์›)๋ณด๋‹ค "์‹ค์งˆ์ ์œผ๋กœ ๋” ๋†’์„ ๊ฒƒ"์ด๋ผ๋Š” ์˜ˆ๊ณ ๊ฐ€ ์ฃผ๊ฐ€์— ์••๋ฐ•์„ ๊ฐ€ํ–ˆ๋‹ค๊ณ  Seeking Alpha๊ฐ€ ์ „ํ–ˆ๋‹ค. ์ „์ผ ๋ฐœํ‘œ๋œ Microsoft Azure +48%CC(์ฃผ๊ฐ€ +5%), Alphabet Google Cloud +103%(EPS ๋ฏธ์Šคยท์ฃผ๊ฐ€ -10%)์™€ ํ•จ๊ป˜ ๋น…ํ…Œํฌ 3์‚ฌ AI ํด๋ผ์šฐ๋“œ ์–ด๋‹์Šค ์‹œ์ฆŒ์ด ๋งˆ๋ฌด๋ฆฌ๋๋‹ค.

โ†— Benzinga โ€” Q3 ์–ด๋‹์Šค์ฝœ

Macro

4. US GDP Q3 +3.4% SAAR โ€” ์ปจ์„ผ์„œ์Šค ์ƒํšŒ, 12์›” FOMC ์ธ์ƒ ์••๋ ฅ ๊ฐ•ํ™”

๋ฏธ๊ตญ ๊ฒฝ์ œ๋ถ„์„๊ตญ(BEA)์ด Q3 2026 GDP 1์ฐจ ์ถ”์ •์น˜๋ฅผ ์ „๊ธฐ ๋Œ€๋น„ ์—ฐ์œจ(SAAR) 3.4%(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”)๋กœ ๋ฐœํ‘œํ–ˆ๋‹ค. ์ปจ์„ผ์„œ์Šค(3.2%)์™€ ์• ํ‹€๋žœํƒ€ Fed GDPNow ์ตœ์ข…์น˜(3.3%) ๋ชจ๋‘๋ฅผ ์›ƒ๋Œ์•˜๋‹ค. Q2 2.2%์—์„œ 1.2%ํฌ์ธํŠธ ๊ฐ€์†์ด๋‹ค. GDP ๋‚ด์žฌ ์ฝ”์–ด PCE deflator๋Š” Q3 ๋ถ„๊ธฐ ํ‰๊ท  2.5%๋ฅผ ๊ธฐ๋กํ–ˆ๋‹ค. ๊ฐ•ํ•œ ์„ฑ์žฅ๊ณผ 2% ๋ชฉํ‘œ๋ฅผ ์•„์ง ์›ƒ๋„๋Š” ๋ฌผ๊ฐ€๊ฐ€ ๊ฒฐํ•ฉ๋˜๋ฉด์„œ FOMC ๋‚ด ๊ฐ•๊ฒฝํŒŒ(CookยทHammack) ๋…ผ๊ฑฐ์— ํž˜์ด ์‹ค๋ ธ๋‹ค๋Š” ๋ถ„์„์ด ๋‚˜์˜จ๋‹ค. 12์›” FOMC(12์›” 8~9์ผ) ์ธ์ƒ์„ ๋ฐ˜์˜ํ•˜๋Š” ์˜ค๋ฒ„๋‚˜์ดํŠธ ์ธ๋ฑ์Šค ์Šค์™‘(OIS) ํ™•๋ฅ ์€ ์•ฝ 80%๋ฅผ ์œ ์ง€ํ•˜๊ณ  ์žˆ๋‹ค. ๋ฐฉํ–ฅ์„ ๊ฐ€๋ฅผ ๋ฐ์ดํ„ฐ๋Š” 11์›” ๊ณ ์šฉ๋ณด๊ณ ์„œ(11/7)์™€ 11์›” CPI(11/13)๋‹ค.

โ†— BEA News Release

Market

5. Eli Lilly Q3 FY2026 โ€” tirzepatide ํ•ฉ์‚ฐ $16.05B, ์„ฑ์žฅ๋ฅ  ๋‘”ํ™” vs ๊ตฌ์กฐ์  ์‹œ์žฅ ์ง€๋ฐฐ ๋…ผ์Ÿ

Eli Lilly(์ผ๋ผ์ด ๋ฆด๋ฆฌ)๊ฐ€ Q3 FY2026 ๋งค์ถœ 244์–ต๋‹ฌ๋Ÿฌ(์•ฝ 33์กฐ8,000์–ต์›, +39% YoY)๋ฅผ ๋ฐœํ‘œํ–ˆ๋‹ค. GLP-1(๊ธ€๋ฃจ์นด๊ณค ์œ ์‚ฌ ํŽฉํƒ€์ด๋“œ-1) ๊ธฐ๋ฐ˜ tirzepatide(ํ‹ฐ๋ฅด์ œํŒŒํƒ€์ด๋“œ) ๋‘ ์ œํ’ˆ์ด ์„ฑ์žฅ์„ ์ฃผ๋„ํ–ˆ๋‹ค. Mounjaro(๋งˆ์šด์ž๋กœยท2ํ˜• ๋‹น๋‡จ+์‹ฌํ˜ˆ๊ด€)๋Š” 107์–ต๋‹ฌ๋Ÿฌ(์•ฝ 14์กฐ8,000์–ต์›, +65% YoY), Zepbound(์ ญ๋ฐ”์šด๋“œยท๋น„๋งŒ)๋Š” 53์–ต๋‹ฌ๋Ÿฌ(์•ฝ 7์กฐ3,000์–ต์›, +48% YoY)๋ฅผ ๊ธฐ๋กํ–ˆ๋‹ค. ๋‘ ์ œํ’ˆ ํ•ฉ์‚ฐ 160์–ต๋‹ฌ๋Ÿฌ(์•ฝ 22์กฐ1,000์–ต์›)๋Š” ์—ฐ์œจ ํ™˜์‚ฐ ์•ฝ 640์–ต๋‹ฌ๋Ÿฌ(์•ฝ 88์กฐ6,000์–ต์›) ๊ทœ๋ชจ๋‹ค. Mounjaro์˜ ์‹ฌํ˜ˆ๊ด€๊ณ„ ์œ„ํ—˜ ๊ฐ์†Œ ์ ์‘์ฆ FDA ์ถ”๊ฐ€ ์Šน์ธ๋„ ์ด๋ฒˆ ๋ถ„๊ธฐ์— ์™„๋ฃŒ๋๋‹ค๊ณ  ๋ฐํ˜”๋‹ค. Q2 ์„ฑ์žฅ๋ฅ  +48%์—์„œ Q3 +39%๋กœ ๋‚ฎ์•„์ง„ ๊ฒƒ์„ ๋‘๊ณ  ๊ธฐ์ €ํšจ๊ณผยท์‹œ์žฅ ์„ฑ์ˆ™ํ™”์˜ ์ž์—ฐ์Šค๋Ÿฌ์šด ํ˜„์ƒ์ด๋ผ๋Š” ํ•ด์„๊ณผ Novo Nordisk ๊ฒฝ๊ตฌ Wegovy ๊ฒฝ์Ÿ ๋ฐ˜์˜์ด๋ผ๋Š” ํ•ด์„์ด ์—‡๊ฐˆ๋ฆฌ๊ณ  ์žˆ๋‹ค.

โ†— Eli Lilly SEC 8-K Q3 2026

๐Ÿ—ฃ ์˜ค๋Š˜์˜ ํ™”์ œ

mRNA ๊ฐœ์ธ๋งž์ถค ์•”๋ฐฑ์‹ ์ด Phase 3์—์„œ ์ฒ˜์Œ์œผ๋กœ ์žฌ๋ฐœยท์‚ฌ๋ง ์ง€ํ‘œ๋ฅผ ๋™์‹œ ๋‹ฌ์„ฑํ–ˆ๋‹ค. ํ”Œ๋žซํผ ์‹ ๋ขฐ๋„๋Š” ํ™•์ธ๋๊ณ , ๋‚จ์€ ๊ด€๋ฌธ์€ ์ œ์กฐ ํ™•์žฅ๊ณผ ์•ฝ๊ฐ€ยท๊ธ‰์—ฌ ํ˜‘์ƒ์ด๋‹ค.

์ „์ฒด ๋ฆฌํฌํŠธ ๋ณด๊ธฐ โ†’

Deep Dive ยท Demand ยท Investment ยท Companies ยท Sources ์ „์ฒด๋Š” ์œ„ ๋งํฌ์—์„œ ๋ณด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ…”๋ ˆ๊ทธ๋žจ @econradar ๋กœ๋„ ๋ฐ›๊ธฐ

econ-radar ยท 2026-10-30

ํˆฌ์ž ์ฐธ๊ณ ์šฉ ์ •๋ณด์ž…๋‹ˆ๋‹ค. ์ตœ์ข… ํŒ๋‹จ๊ณผ ์ฑ…์ž„์€ ๋ณธ์ธ์—๊ฒŒ ์žˆ์Šต๋‹ˆ๋‹ค.

Don't miss what's next. Subscribe to Kakyung Kim:
โ† Newer ๐Ÿ“ˆ econ-radar 2026-10-31 ยท ๊ตญ๋‚ด GLP-1 ์ƒํƒœ๊ณ„(Korea GLP-1 Ecosystem) Older โ†’ ๐Ÿ“ˆ econ-radar 2026-10-29 ยท Anthropic IPO: ์ƒ์„ฑํ˜• AI ๊ธฐ์—…์ด ๊ณต๊ฐœ์‹œ์žฅ์— ์ฒ˜์Œ ์„œ๋Š” ๋‚ 
Powered by Buttondown, the easiest way to start and grow your newsletter.